The robot that shares a workbench with a human, rather than hiding behind a cage, has been a Silicon Valley talking point for a decade. The company that just proved it can be a public business is from Shenzhen.
Shenzhen Dobot Corp (越疆科技, 02432.HK) began trading on the Hong Kong Stock Exchange on December 23, 2024, at an offer price of HK$18.80. It raised HK$752 million in gross proceeds (≈ US$96M) and HK$681 million net (≈ US$87M), becoming the first Chinese manufacturer of collaborative robots (协作机器人) — cobots — to reach a public market. The shares closed their debut essentially flat, a muted reception for a firm that calls itself the largest cobot maker in China.
Key takeaways
- Dobot's IPO delivered HK$752M gross (≈ US$96M) and HK$681M net (≈ US$87M) at HK$18.80 per share.
- It is described as the largest cobot (协作机器人) company in China and second globally with roughly a 13% share, per research cited by local government.
- Revenue in 2023 was ¥287 million (≈ US$40M), but the company remains loss-making, losing ¥103 million that year.
- More than half of sales already come from outside China, a rare trait for a domestic industrial-robot firm.
A quiet machine with a loud thesis
A collaborative robot is an articulated arm built to work safely next to people — no fence, no cage, often teachable by hand-guiding. Dobot's catalog spans four-axis, six-axis, and compound cobots used in education, light industry, retail, healthcare, and chemicals. That sounds unglamorous next to humanoids (人形机器人) that walk on stages, but cobots are where robotics revenue actually shows up today: repeatable, priced, and shipped.
The reason a modestly sized maker drew a Hong Kong listing is the same reason its rival JAKA reportedly pulled a Shanghai Star Market attempt and peer Aubo has only rumored filings. Public markets reward a clean story of global demand and overseas revenue, and Dobot's pitch fits: as of late 2023 its products reached more than 80 countries and regions, with overseas markets contributing about 59% of revenue, up from 48% in 2021.
What the proceeds are meant to build
The net proceeds are pointed squarely at the next five years. According to the prospectus, the plan runs 2025–2029 and splits roughly into: cutting-edge development of intelligent cobots, expansion of production lines and manufacturing capacity, selective alliances or acquisitions among downstream cobot integrators, building overseas sales channels, and general working capital.
In plain terms, Dobot is using the listing to do two things at once — deepen its technology and widen its footprint abroad. That is a rational use of capital for a company whose growth constraint has been scale and brand reach outside China, not proof that the product works.
The profitability caveat
Investors should not confuse a successful listing with a healthy bottom line. Dobot posted losses of ¥59.9 million (≈ US$8.2M) in the first half of 2024 and ¥103 million for all of 2023, and its prospectus warns it may not turn a profit in the near term given R&D and expansion spending. Revenue did climb 9.6% in the first half of 2024 to ¥121 million, but the path to black ink depends on whether cobot adoption accelerates faster than the cost of chasing it.
The market's tepid debut — a 0.74% first-day gain after briefly dipping below the offer price — suggests investors priced in exactly that uncertainty. A cobot maker's value is not in one quarter's shipment but in whether the category becomes default equipment on factory and classroom floors worldwide.
Why it matters beyond the ticker
Dobot's listing is a useful data point for anyone tracking China's robotics exports. Unlike many domestic automation firms that live or die on local factory orders, Dobot earns a majority of revenue offshore. That makes it a cleaner read on global willingness to buy Chinese robotic arms — a trend with implications for established players in Europe and Japan.
It also marks a shift in where Chinese robotics firms raise money. Hong Kong, with its international investor base and lighter path than a mainland tech-board listing, is becoming the default venue for companies that want both a China story and global capital.
What readers can do now
- Benchmark cobot adoption, not just the stock. Watch unit shipments and average selling prices in Dobot's reported segments (education, light industry, healthcare) as a real-economy signal.
- Follow the overseas share. Dobot's ~59% foreign revenue is its differentiator; a sustained rise confirms genuine global demand rather than domestic subsidy.
- Compare the peer set. Track JAKA, Aubo, and international cobot names (e.g., Denmark's OnRobot-class vendors) to see whether Dobot's "largest in China" claim holds as rivals list.
Honest limitations
Figures here come from Dobot's HKEX final offering announcement, the company's prospectus, and reporting by the Shenzhen Nanshan district government and state-affiliated financial media (中国经济网). The "largest in China, second globally with ~13% share" claim is attributed to research firm China Insights Consultancy as cited by local government; I have not independently verified that market-share data. Listing date, offer price, and proceeds are confirmed from the exchange filing. Loss figures are taken from the prospectus and may be revised in audited reports. I hold no position in Dobot and have no affiliation with the company.